Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind vehicle-controlled study of topical TCP-25 in epidermolysis bullosa
2024-515172-12-00Phase 2Authorised
- Sponsor
- Xinnate
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Hydrogel Systems → Drug Delivery Systems
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in epidermolysis bullosa (EB), dystrophic epidermolysis bullosa (DEB) and junctional epidermolysis bullosa (JEB) comparing TCP-25 gel with Vehicle control (2 arms). Planned start Dec 2025; status: authorised.
02
Drugs
tcp-25
03
Conditions
epidermolysis bullosa (EB)dystrophic epidermolysis bullosa (DEB)junctional epidermolysis bullosa (JEB)
Beyond the preview
Go deeper on 2024-515172-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515172-12-00.